rood blauwe elepsis logo Belegger.nl

BioPharma Terug naar discussie overzicht

Nieuws GTCB

7 Posts
| Omlaag ↓
  1. Huppeldepepup 25 januari 2006 12:00
    Als dat toch eens waar is.

    From Sheep to Salvation: GTC Biotherapeutics’ Antithrombin Medicine Nears Approv


    Confidential sources have indicated that the European FDA, the European Medicines Agency (EMEA) has given positive feedback on GTC Biotherapeutics’ Antithrombin drug, as it nears European Common Market approval.

    Antithrombin deficiency, also known, as Antithrombin III deficiency is one of the most prevalent genetically acquired coagulation deficiencies in man. It inhibits virtually all the coagulation enzymes in the coagulation cascade as well as allows heparin to function as an anticoagulant; likewise, it binds to heparin rapidly, making the antithrombin-heparin complex a vital component of coagulation. It is autosomal dominant i.e. it takes only the presence of one copy of the gene to cause disease or adverse event. So, when an individual is unfortunate to have acquired both defective genes as in type I Antithrombin deficiency, he never makes it out alive. The fetus is killed by a massive blood clot or thrombosis prior to birth. There is usually a pattern of severe arterial and venous thrombosis with type! II homozygous Antithrombin deficiency that is also caused by both defective genes being present.

    The prevalence in the U.S .of Antithrombin deficiency is estimated to be as low as one in 5,000 to as high as one in one hundred individuals. These individuals are often undiagnosed and are at risk for repeated episodes of life threatening clots such as DVT’s (deep venous thrombosis), or P.E’s (pulmonary emboli). These episodes usually appear after the age of 20, with risk factors such as age, surgery, pregnancy, labor and delivery. The frequency of blood clots in an Antithrombin-deficient pregnant female has been estimated to be a whopping 70%. As a person ages, the risk of a clot increases exponentially. An astounding 85% of individuals with the deficiency over the age of 50 have had a thromboembolic event.

    While most patients who have suffered a clot are placed on low- molecular -weight heparin or warfarin, the latter is contraindicated during pregnancy and the former may not be effective following major surgery. This is where the potential use of Antithrombin has been used. Unfortunately, it is made from concentrating the factor out of numerous blood donors, many of whom are street people infected with various viruses not yet screened for such as hepatitis D, E, F, G, H and I, or even those not yet discovered. Not only is the potential for acquiring a harmful virus present, the human concentrate is expensive- up to $7000 a gram.

    GTC Biotherapeutics used transgenically modified sheep, which had the Antithrombin genes inserted to enable its offspring to inherent and ultimately produce the drug in an efficient cost- effective production method. Production of the medicine could be ramped up in a matter of months instead of years and spending hundreds of millions of dollars to produce vats of bacteria that could produce simple proteins but not the glycosylated proteins that sheep are able to produce. The future has arrived.

    Steven Turner MD, MBA is a physician who performs due diligence financial analysis on biotech as well as tech businesses for several mutual funds. He presently is vice president of the St. Louis Angel Investor Network
  2. [verwijderd] 25 januari 2006 12:03
    moet er daar nou steeds een nieuw draadje voor bij?
    houd het even centraal in de al aanwezige draadjes over gtcb

    verder wel thanks voor het vinden...
    vroeg in gtcb los al: url?
  3. Huppeldepepup 25 januari 2006 12:05
    quote:

    crackedtooth schreef:

    moet er daar nou steeds een nieuw draadje voor bij?
    houd het even centraal in de al aanwezige draadjes over gtcb

    verder wel thanks voor het vinden...
    vroeg in gtcb los al: url?
    Als er iets waars in zit, is het volgens mij wel een eigen draadje waard. "GTCB los" vind ik zo langzaam aan niet leesbaar meer.
  4. ludwig mack 25 januari 2006 14:39
    quote:

    Huppeldepepup schreef:

    [quote=crackedtooth]
    moet er daar nou steeds een nieuw draadje voor bij?
    houd het even centraal in de al aanwezige draadjes over gtcb

    verder wel thanks voor het vinden...
    vroeg in gtcb los al: url?
    [/quote]

    Als er iets waars in zit, is het volgens mij wel een eigen draadje waard. "GTCB los" vind ik zo langzaam aan niet leesbaar meer.
    je moet pagina-instelling op 100 zetten en steeds laatste pagina oproepen;
    we hebben het al zo lang dus oude draadje behouden;
    groet
  5. bali bob 25 januari 2006 19:41
    quote:

    Huppeldepepup schreef:


    Steven Turner MD, MBA is a physician who performs due diligence ...

    En het dan over schapen hebben....
7 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.141
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.328
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.909
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.872
Aedifica 3 927
Aegon 3.258 323.134
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.070
Ahold 3.538 74.353
Air France - KLM 1.025 35.304
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.056
Alfen 16 25.375
Allfunds Group 4 1.520
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.131
AMG 972 134.576
AMS 3 73
Amsterdam Commodities 305 6.747
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 497
Antonov 22.632 153.605
Aperam 92 15.089
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.808
Arcelor Mittal 2.035 321.037
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.362
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.666
ASML 1.766 110.932
ASR Nederland 21 4.517
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.216
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449